Compare MYSZ & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | VIVS |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.5M |
| IPO Year | 2017 | 2010 |
| Metric | MYSZ | VIVS |
|---|---|---|
| Price | $0.43 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.5K | ★ 9.5M |
| Earning Date | 04-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $142,000.00 | ★ $4,603,000.00 |
| Revenue This Year | $41.64 | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | 8.82 |
| 52 Week Low | $0.33 | $0.31 |
| 52 Week High | $1.38 | $5.30 |
| Indicator | MYSZ | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 32.39 |
| Support Level | $0.38 | N/A |
| Resistance Level | $0.50 | $1.88 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 71.77 | 16.75 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.